Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AM-Pharma |
---|---|
Information provided by: | AM-Pharma |
ClinicalTrials.gov Identifier: | NCT00509847 |
The purpose of this study is to establish the tolerability of treatment with human lactoferrin 1-11 peptide (hLF1-11) administered intravenously as a single dose given for 10 consecutive days, to patients with bacteremia due to staphylococcus epidermidis.
Condition | Intervention | Phase |
---|---|---|
Staphylococcal Infections Bacteremia |
Drug: human lactoferrin peptide 1-11 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase-IIa, Double-Blind, Randomized, Controlled Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Bacteremia Due to Staphylococcus Epidermidis |
Estimated Enrollment: | 20 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
RATIONALE FOR THE STUDY
Choice of Drug
Staphylococcus epidermidis is a relatively uncommon find in blood cultures, most cases being found in patients with intravenous lines through contiguous contamination and current clinical practice is often one of not using antibiotic treatment immediately, unless significant clinical signs and symptoms and/or patient status justifies intervention with an antibiotic. The latter tends to be vancomycin as many S epidermidis strains are resistant to other agents.
hLF1-11 is hypothesized to have antibacterial effects against Staphylococcus epidermidis, amongst other strains.
Should hLF1-11 be shown to be an effective antibacterial against Staphylococcus epidermidis, its use would be justified in other more serious hospital-acquired infections such as MRSA for which hLF1-11 has been shown (in preclinical in vitro and in vivo data) to display a strong therapeutic effect.
Choice of Patient Population
Based on preclinical data hLF1-11 has been shown to possess antibacterial effects on the selected bacteria (Staphylococcus epidermidis). Staphylococcus epidermidis is a commensal found in human skin. In current clinical practice hospital-acquired systemic Staphylococcal epidermidis is not routinely treated unless the bacteremia is accompanied by a clear clinical risk to the patient.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Netherlands, Gelderland | |
UMC St. Radboud | |
Nijmegen, Gelderland, Netherlands, 6500 HB | |
UMC St. Radboud | |
Nijmegen, Gelderland, Netherlands, 6500 HB |
Principal Investigator: | Professor P.E. Verweij, MD, PhD | UMC St. Radboud Nijmegen, The Netherlands |
Responsible Party: | AM-Pharma ( Dr J Arend, MD ) |
Study ID Numbers: | AMP SSTI 01-01 |
Study First Received: | July 31, 2007 |
Last Updated: | October 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00509847 |
Health Authority: | Netherlands: Medical Ethics Review Committee (METC); Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
S. epidermidis Staphylococcus Lactoferrin hLF1-11 Bacteraemia |
Systemic Inflammatory Response Syndrome Bacterial Infections Staphylococcal Infections Gram-Positive Bacterial Infections |
Sepsis Bacteremia Inflammation |
Pathologic Processes Infection |